Phase I clinica trial of the use of zinc phthalocyanine tetrasulfonate as a photosensitizer for photodynamic therapy in dogs

American Journal of Veterinary Research

Volumn 68, Issue 4, 2007, Pages 399-404

  Borgatti Jeffreys, Antonella ^a,b   Hooser, Stephen B ^a   Miller, Margaret A ^a   Lucroy, Michael D ^a  

^a PURDUE UNIVERSITY   (United States)

^b Carolina Veterinary Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHTHALOCYANINE ZINC; INDOLE DERIVATIVE; ORGANOMETALLIC COMPOUND; PHOTOSENSITIZING AGENT; TETRASULFOPHTHALOCYANINE ZINC; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; INTOXICATION; KIDNEY TUBULE NECROSIS; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NEOPLASM; NONHUMAN; PHOTODYNAMIC THERAPY; SWISS WEBSTER MOUSE; TUMOR REGRESSION; ANIMAL; ANIMAL DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOG DISEASE; FEMALE; KIDNEY CORTEX NECROSIS; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHOTOCHEMOTHERAPY; TOXICITY TESTING;

ANIMALIA; CANIS FAMILIARIS; MUS;

ANIMALS; DOG DISEASES; DOGS; FEMALE; INDOLES; KIDNEY CORTEX NECROSIS; MALE; MICE; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TOXICITY TESTS;

EID: 34247473871     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.4.399     Document Type: Article

References (34)

1. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004;5:497-508.
2. Cheli R, Addis F, Mortellaro CM, et al. Photodynamic therapy of spontaneous animal tumors using the active component of hematoporphyrin derivative (DHE) as photosensitizing drug: clinical results. Cancer Lett 1987;38:101-105.
3. Frimberger AE, Moore AS, Cincotta L, et al. Photodynamic therapy of naturally occurring tumors in animals using a novel benzophenothiazine photosensitizer. Clin Cancer Res 1998;4:2207-2218.
4. Gloi AM, Beck E. Evaluation of porfimer sodium in dogs and cats with spontaneous tumors. Vet Ther 2004;5:26-33.
5. Jacobs TM, Rosen GM. Photodynamic therapy as a treatment for esophageal squamous cell carcinoma in a dog. J Am Anim Hosp Assoc 2000;36:257-261.
6. Lucroy MD, Bowles MH, Higbee RG, et al. Photodynamic therapy for prostatic carcinoma in a dog. J Vet Intern Med 2003;17:235-237.
7. Lucroy MD, Long KR, Blaik MA, et al. Photodynamic therapy for the treatment of intranasal tumors in 3 dogs and 1 cat. J Vet Intern Med 2003;17:727-729.
8. Lucroy MD, Ridgway TD, Peavy GM, et al. Preclinical evaluation of 5-aminolevulinic acid-based photodynamic therapy for canine transitional cell carcinoma. Vet Comp Oncol 2003;1:76-85.
9. Magne ML, Rodriguez CO, Autry SA, et al. Photodynamic therapy of facial squamous cell carcinoma in cats using a new photosensitizer. Lasers Surg Med 1997;20:202-209.
10. McCaw DL, Payne JT, Pope ER, et al. Treatment of canine hemangiopericytomas with photodynamic therapy. Lasers Surg Med 2001;29:23-26.
11. McCaw DL, Pope ER, Payne JT, et al. Treatment of canine oral squamous cell carcinomas with photodynamic therapy. Br J Cancer 2000;82:1297-1299.
12. Peaston AE, Leach MW Higgins RJ. Photodynamic therapy for nasal and aural squamous cell carcinoma in cats. J Am Vet Med Assoc 1993;202:1261-1265.
13. Roberts WG, Klein MK, Loomis M, et al. Photodynamic therapy of spontaneous cancers in felines, canines, and snakes with chloro-aluminum sulfonated phthalocyanine. J Natl Cancer Inst 1991;83:18-23.
14. Lucroy MD, Edwards BF, Madewell BR. Veterinary photodynamic therapy. J Am Vet Med Assoc 2000;216:1745-1751.
15. Lucroy MD, Magne ML, Peavy GM, et al. Photodynamic therapy in veterinary medicine: current status and implications for applications in human disease. J Clin Laser Med Surg 1996;14:305-310.
16. Wolfsen HC, Ng CS. Cutaneous consequences of photodynamic therapy. Cutis 2002;69:140-142.
17. Lucroy MD, Edwards BF, Peavy GM, et al. Preclinical study in cats of the pro-photosensitizer 5-aminolevulinic acid. Am J Vet Res 1999;60:1364-1370.
18. Hahn KA, Panjehpour M, Legendre AM. Photodynamic therapy response in cats with cutaneous squamous cell carcinoma as a function of fluence. Vet Dermatol 1998;9:3-7.
19. Leach MW, Peaston AE. Adverse drug reaction attributable to aluminum phthalocyanine tetrasulphonate administration in domestic cats. Vet Pathol 1994;31:283-287.
20. Reeds KB, Ridgway TD, Higbee RG, et al. Non-coherent light for photodynamic therapy of superficial tumours in animals. Vet Comp Oncol 2004;2:157-163.
21. Lucroy MD. Photodynamic therapy for companion animals with cancer. Vet Clin North Am Small Anim Pract 2002;32:693-702, viii.
22. Fingar VH, Wieman TJ, Karavolos PS, et al. The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage and tumor response. Photochem Photobiol 1993;58:251-258.
23. Howe L, Zhang JZ. The effect of biological substrates on the ultrafast excited-state dynamics of zinc phthalocyanine tetrasulfonate in solution. Photochem Photobiol 1998;67:90-96.
24. Margaron P, Gregoire MJ, Scasnar V, et al. Structure-photodynamic activity relationships of a series of 4-substituted zinc phthalocyanines. Photochem Photobiol 1996;63:217-223.
25. Reddi E, Lo Castro G, Biolo R, et al. Pharmacokinetic studies with zinc(II)-phthalocyanine in tumour-bearing mice. Br J Cancer 1987;56:597-600.
26. Spikes JD, Bommer JC. Zinc tetrasulphophthalocyanine as a photodynamic sensitizer for biomolecules. Int J Radiat Biol Relat Stud Phys Chem Med 1986;50:41-45.
27. Fabris C, Valduga G, Miotto G, et al. Photosensitization with zinc (II) phthalocyanine as a switch in the decision between apoptosis and necrosis. Cancer Res 2001;61:7495-7500.
28. Haywood-Small SL, Vernon DI, Griffiths J, et al. Phthalocyanine-mediated photodynamic therapy induces cell death and a G0/G1 cell cycle arrest in cervical cancer cells. Biochem Biophys Res Commun 2006; 339:569-576.
29. Shopova M, Mantareva V, Krastev K, et al. Comparative pharmacokinetic and photodynamic studies with zinc(II) phthalocyanine in hamsters bearing an induced or transplanted rhabdomyosarcoma. J Photochem Photobiol B 1992;16:83-89.
30. van Leengoed HL, van der Veen N, Versteeg AA, et al. In vivo photodynamic effects of phthalocyanines in a skin-fold observation chamber model: role of central metal ion and degree of sulfonation. Photochem Photobiol 1993;58:575-580.
31. Villanueva A, Dominguez V, Polo S, et al. Photokilling mechanisms induced by zinc(II)-phthalocyanine on cultured tumor cells. Oncol Res 1999;11:447-453.
32. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-1147.
33. Bown SG, Tralau CJ, Smith PD, et al. Photodynamic therapy with porphyrin and phthalocyanine sensitisation: quantitative studies in normal rat liver. Br J Cancer 1986;54:43-52.
34. Wilson BC, Patterson MS, Burns DM. Effect of photosensitizer concentration in tissue on the penetration depth of photoactivating light. Lasers Med Sci 1986;1:235-244.